AstraZeneca ( AZN ) and its partner Rigel Pharmaceuticals ( RIGL ) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib for
Target Corporation ( TGT ), the operator of general merchandise and food discount stores in the United States, announced the opening of its third store in Baltimore, Maryland. The new
Isis Pharmaceuticals Inc. ( ISIS ) and AstraZeneca ( AZN ) recently announced that they have entered into an agreement to discover and develop five new generation antisense oncology